IRIS
MUSOLINO, Antonino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.445
AS - Asia 6.423
EU - Europa 3.389
SA - Sud America 1.032
AF - Africa 389
Continente sconosciuto - Info sul continente non disponibili 277
OC - Oceania 9
Totale 17.964
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.200
SG - Singapore 2.660
CN - Cina 1.205
VN - Vietnam 1.043
IE - Irlanda 838
BR - Brasile 766
IT - Italia 659
HK - Hong Kong 550
SE - Svezia 401
BD - Bangladesh 373
DE - Germania 373
ZA - Sudafrica 245
FR - Francia 234
NL - Olanda 231
CA - Canada 131
IN - India 121
FI - Finlandia 112
GB - Regno Unito 112
AR - Argentina 91
RU - Federazione Russa 84
UA - Ucraina 78
AT - Austria 73
IQ - Iraq 56
TR - Turchia 55
MX - Messico 48
EC - Ecuador 46
PH - Filippine 41
PK - Pakistan 40
BE - Belgio 39
CO - Colombia 38
CI - Costa d'Avorio 37
PL - Polonia 37
ES - Italia 35
ID - Indonesia 35
JP - Giappone 30
VE - Venezuela 30
KR - Corea 28
MY - Malesia 26
CL - Cile 22
MA - Marocco 22
SA - Arabia Saudita 20
TW - Taiwan 20
TH - Thailandia 19
UZ - Uzbekistan 19
A1 - Anonimo 16
KE - Kenya 16
TN - Tunisia 16
PY - Paraguay 15
CR - Costa Rica 12
CZ - Repubblica Ceca 12
AE - Emirati Arabi Uniti 11
EG - Egitto 11
LT - Lituania 11
UY - Uruguay 10
DZ - Algeria 8
IL - Israele 8
NI - Nicaragua 8
BO - Bolivia 7
IR - Iran 7
JM - Giamaica 7
JO - Giordania 7
PE - Perù 7
TT - Trinidad e Tobago 7
AL - Albania 6
AU - Australia 6
AZ - Azerbaigian 6
DO - Repubblica Dominicana 6
ET - Etiopia 6
HN - Honduras 6
HR - Croazia 6
NG - Nigeria 6
PS - Palestinian Territory 6
HU - Ungheria 5
NP - Nepal 5
OM - Oman 5
PA - Panama 5
RO - Romania 5
SY - Repubblica araba siriana 5
BG - Bulgaria 4
EU - Europa 4
GT - Guatemala 4
PT - Portogallo 4
SI - Slovenia 4
SV - El Salvador 4
BA - Bosnia-Erzegovina 3
BB - Barbados 3
BH - Bahrain 3
CH - Svizzera 3
KZ - Kazakistan 3
LB - Libano 3
LK - Sri Lanka 3
LY - Libia 3
MU - Mauritius 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
BY - Bielorussia 2
CG - Congo 2
GH - Ghana 2
GR - Grecia 2
Totale 17.671
Salva come PNG Salva come JPEG
Città #
Singapore 1.321
Ashburn 837
Dublin 822
San Jose 737
Chandler 668
Hong Kong 517
Santa Clara 485
Beijing 462
Ho Chi Minh City 309
Council Bluffs 244
Boardman 234
Hanoi 231
Johannesburg 225
Dallas 221
Lauterbourg 165
New York 164
Princeton 147
Ann Arbor 140
Los Angeles 134
Shanghai 117
Bremen 106
Des Moines 85
Milan 81
Helsinki 73
Parma 69
São Paulo 65
Seattle 64
Jacksonville 62
Munich 62
Vienna 60
Grafing 57
Moscow 55
Wilmington 55
Montreal 53
Buffalo 51
Da Nang 50
Haiphong 47
Rome 45
Hefei 43
Frankfurt am Main 39
Abidjan 37
Columbus 37
Phoenix 36
Toronto 34
Brussels 32
Dearborn 32
Bologna 31
Nuremberg 31
Rio de Janeiro 28
Brooklyn 27
Nanjing 25
San Mateo 23
Tokyo 23
Baghdad 22
Stockholm 22
The Dalles 20
Amsterdam 19
Naples 19
Shenyang 19
Warsaw 19
Atlanta 18
Belo Horizonte 18
Denver 18
London 18
Tashkent 18
Brasília 17
Chicago 17
Hải Dương 17
Jinan 17
Jakarta 16
Charlotte 15
Fairfield 15
Istanbul 15
Woodbridge 15
Biên Hòa 14
Boston 14
Curitiba 14
Houston 14
Nairobi 14
Orem 14
Can Tho 13
Changsha 13
Dhaka 13
Pune 13
Tianjin 13
Ardea 12
Fremont 12
Lahore 12
Madrid 12
Poplar 12
Rio Saliceto 12
Thái Bình 12
Bogotá 11
Campinas 11
Guayaquil 11
Salvador 11
San Francisco 11
Bangkok 10
Borås 10
Cape Town 10
Totale 10.490
Salva come PNG Salva come JPEG
Nome #
Role of immunoglobulin G fragment C receptor polymorphism-mediatedantibody-dependant1. cellular cytotoxicity in colorectal cancer treated withcetuximab therapy. Pharmacogenomics J. 302
SARS-CoV-2 Infection Risk and COVID-19 Prevalence and Mortality in Cancer Patients During the First Wave of COVID-19 Pandemic in a Virus Epicenter in Northern Italy 189
Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma 167
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial 164
1134 POSTER Survival prediction of terminally ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators 164
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy 162
[68Ga]Nivolumab: a novel PET tracer to detect PD-1 expressing tumors 161
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 161
Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis 159
Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing 157
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 156
Abstract P1-14-05: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE Trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 155
Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression 153
Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers 153
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 151
BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study 151
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 150
The Breast Avastin Trial: Phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer 150
Salivary microRNA for diagnosis of cancer and systemic diseases: A systematic review 149
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER 147
Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient 145
Prognostic impact of interval breast cancer detection in women with pT1aN0M0 breast cancer with HER2-positive status: results from a multicenter population-based cancer registry study 145
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study 144
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 143
p73 and p53 pathway in human breast cancers. 141
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 140
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016) 139
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study 139
522 POSTER Immunoglobulin G fragment C receptor polymorphisms and clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with cetuximab-based therapy 137
Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force 137
Abstract OT1-03-03: Phase II, open label, randomized, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with operable or locally advanced/Inflammatory HER2-positive breast cancer. ImmunHER trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 136
Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer 135
A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes 132
Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu-Positive Metastatic Breast Cancer. 132
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer 132
A review of immune checkpoint blockade in breast cancer 130
Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review 128
Accuracy and relative value of bone marrow aspiration in the detection of lymphoid infiltration in non-Hodgkin lymphoma 127
20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years 126
Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review 126
Lung cancer in patients with chronic lymphocytic leukemia: does the HER-2 oncogene play a role? 125
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 125
Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based study 124
Activity and Safety of DoseAdjusted Infusional Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy With Rituximab in Very Elderly Patients With PoorPrognostic Untreated Diffuse Large B Cell Non Hodgkin Lymphoma 124
My best choice after a round trip from illness 124
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer 119
BRCA STATUS, MOLECULAR PROFILE AND CLINICAL VARIABLES IN PRIMARY BILATERAL BREAST CANCERS: A POPULATION-BASED CANCER REGISTRY STUDY 118
A narrative review of the principal glucocorticoids employed in cancer 118
BOLERO-3 results: Pharmacological activity or pharmacokinetic effect? 116
Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/NEU-positive metastatic breast cancer 116
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 115
Mechanism of action and clinical efficacy of CDK4/6 inhibitors in BRCA-mutated, estrogen receptor-positive breast cancers: Case report and literature review 114
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study ShortHER 114
ACTIVITY AND SAFETY OF DOSEADJUSTED INFUSIONAL CHOP CHEMOTHERAPY WITH RITUXIMAB (DAPOCHR) IN VERY ELDERLY PATIENTS WITH POORPROGNOSTIC UNTREATED DIFFUSE LARGE BCELL NONHODGKIN'S LYMPHOMA 114
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study 114
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 113
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 112
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial 111
Long-Term Effects of Breast Cancer Therapy and Care: Calm after the Storm? 111
Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study 111
Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents 110
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio 108
In reply 108
Evaluation of an Italian Population-Based Programme for Risk Assessment and Genetic Counselling and Testing for BRCA1/2-Related Hereditary Breast and Ovarian Cancer after 10 Years of Operation: An Observational Study Protocol 107
Prognostic role of immunoglobulin g fragment c receptor polymorphisms in solid tumors 107
Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma 106
The future potential of genome-wide mutational profiles in HRD detection in breast cancer 106
Molecular subtypes, metastatic pattern and patient age in breast cancer: An analysis of italian network of cancer registries (airtum) data 106
Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies 105
Survival predisction of terminally ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators 104
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy 104
Indicators of cure for women living after uterine and ovarian cancers: a population-based study 103
Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 103
Phase II Study of Bevacizumab in Combination with Docetaxel and Capecitabine for the First Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer 103
EFFICACY AND SAFETY OF THE ASSOCIATION OF PACLITAXEL AND ESTRAMUSTINE WITH ZOLENDRONIC ACID, IN METASTATIC HORMONE REFRACTORY PROSTATE CARCINOMA 102
Male breast cancer in Parma Province: Descriptive epidemiology, molecular markers and clinical variables 101
Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients 100
La fototerapia mirata bath-puva come trattamento di alcune reazioni cutanee avverse causte da farmaci inibitori delle tirosina-Kinasi (TKI) 100
Hypertriglyceridaemia with bexarotene in cutaneous T-cell lymphoma: The role of omega-3 fatty acids. 99
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials 98
Risk of breast cancer in ovarian cancer patients non-carriers of BRCA1 and BRCA2 mutations with a family history of breast and ovarian cancer: A population-based cancer registry study 97
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification 96
Role of Fcγ receptors in HER2-targeted breast cancer therapy 95
The relative contribution of the decreasing tumour thickness trend to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population‐based investigation 95
Breast Cancer in Italy: Stage and Region Distribution 94
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 93
Correlation between HER2/ neu amplification in fine needle aspirates from breast carcinoma and responses to neoadjuvant anthracycline based chemotherapy 93
Brain metastasis (BM) prediction by transcriptomic profiling in triple-negative breast cancer (TNBC) 93
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors 92
Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2 positive breast cancers 92
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 92
Survival prediction of terminally Ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators 91
Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998-2012 91
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial 89
Survival prediction of terminally Ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators. 89
A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA) 88
Intracranial hematopoiesis in a patient with AIDS-related central nervous system lymphoma and severe pancytopenia. 88
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer 88
Patients with cancer who will be cured and projections of complete prevalence in Italy from 2018 to 2030 87
Different expression of BRCA1 status and clinical variables in a sample of Italian women with early onset breast cancer (EOBC) 87
Totale 12.263
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.650
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.650
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022588 0 0 24 28 16 67 32 42 41 26 26 286
2022/20232.680 328 196 134 177 260 255 18 183 952 23 122 32
2023/20241.097 53 112 16 32 97 225 106 117 40 79 64 156
2024/20253.531 70 209 285 171 394 315 91 114 476 383 293 730
2025/20267.975 660 754 906 589 988 347 944 211 1.037 683 476 380
2026/2027866 177 378 311 0 0 0 0 0 0 0 0 0
Totale 17.964